shutterstock_2320390405_rafapress

5 December 2023Big PharmaLiz Hockley

US biotech wins review of rival’s endocrine patents after Vidal intervention

USPTO director remanded case back to PTAB after it denied post-grant review of Spruce patents | Judges determined likelihood of claims being unpatentable due to prior art and lack of written description.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotechnology

Vidal overturns PTAB decision on pig vaccine patent

2 March 2023 Boehringer Ingelheim challenged university patent | Board must provide more details on ruling.

Vidal issues non-binding guidance on Fintiv denials

23 June 2022 The director of the US Patent and Trademark Office, Kathi Vidal, has unveiled long-anticipated guidance for the procedures governing the discretionary denials that can be handed down by the US Patent Trial and Appeal Board (PTAB) when declining to review a patent’s validity.

More on this story

Biotechnology

Vidal overturns PTAB decision on pig vaccine patent

2 March 2023 Boehringer Ingelheim challenged university patent | Board must provide more details on ruling.

Vidal issues non-binding guidance on Fintiv denials

23 June 2022 The director of the US Patent and Trademark Office, Kathi Vidal, has unveiled long-anticipated guidance for the procedures governing the discretionary denials that can be handed down by the US Patent Trial and Appeal Board (PTAB) when declining to review a patent’s validity.

More on this story

Biotechnology

Vidal overturns PTAB decision on pig vaccine patent

2 March 2023 Boehringer Ingelheim challenged university patent | Board must provide more details on ruling.

Vidal issues non-binding guidance on Fintiv denials

23 June 2022 The director of the US Patent and Trademark Office, Kathi Vidal, has unveiled long-anticipated guidance for the procedures governing the discretionary denials that can be handed down by the US Patent Trial and Appeal Board (PTAB) when declining to review a patent’s validity.

More features

Bayer gains exclusive licence for heart drug in Japan

EPO delivers key Novo Nordisk, GSK and Inhibrx rulings

McGuireWoods expands team with ex-Novo Nordisk GC

Paul, Weiss swoops for senior duo from Weil, Gotshal

UPC bans Meril Life Sciences from selling infringing heart valve

SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic

Kathi Vidal to rejoin previous firm as partner following USPTO departure

GSK triumphs in EPO appeal, revoking Pfizer patent